Keeping Track: US FDA Approvals For Ibsrela, Gvoke And Nucala; A BTD For Tepotinib

The latest drug development news and highlights from our US FDA Performance Tracker. 

Keeping Track Feature image

The US Food and Drug Administration got right back into the novel drug approval game after a week off, giving its go-ahead to Ardelyx Inc.'s Ibsrela (tenapanor) for the treatment of irritable bowel syndrome with constipation (IBS-C). The Center for Drug Evaluation and Research has now approved 27 novel drugs in 2019.

Another notable approval went to a non-novel product:Xeris Pharmaceuticals Inc.'s Gvoke (glucagon) for the treatment of severe hypoglycemia. Gvoke...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from US FDA Performance Tracker

More from Regulatory Trackers